Business
Genentech Announces Agreement With U.S. Government
SOUTH SAN FRANCISCO, Calif., December 19, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced an agreement with the U.S. government that lowers costs for state Medicaid programs, encourages other wealthy countries to reward innovation, and increases opportunities for direct patient access.
About this update from Roche Holding Ltd
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/a8dab848e38d3349104bd2293ef5abec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rdztEtddEdXH8ldDc7stwA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a8dab848e38d3349104bd2293ef5abec","width":480,"height":480}},"lazy":false},{"type":"text","content":"– Agreement with the U.S. government addresses prescription drug costs and encourages other wealthy nations to reward biopharmaceutical innovation –","length":148,"tagName":"p","attribs":{}},{"type":"text","content":"– Influenza portfolio to be made available through TrumpRx.gov and through Genentech’s recently-launched direct-to-patient program –","length":132,"tagName":"p","attribs":{}},{"type":"text","content":"– Company commitment to U.S. manufacturing, infrastructure, and R&D reaffirmed, building on the recent $50 billion investment announcement and recent groundbreaking of new manufacturing facility in North Carolina –","length":218,"tagName":"p","attribs":{}},{"type":"text","content":"– Government exempts Genentech portfolio from tariffs, enabling Genentech’s continued investment and expansion of its manufacturing footprint in the U.S. –","length":155,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., December 19, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced an agreement with the U.S. government that lowers costs for state Medicaid programs, encourages other wealthy countries to reward innovation, and increases opportunities for direct patient access.","length":340,"tagName":"p"},{"type":"text","content":"Under this agreement, Genentech is making commitments that address all four priorities set forth in the President’s July 31st letter. Genentech’s commitments include making many of the company’s medicines, including those for serious and complex diseases, available as part of Medicaid for America’s most vulnerable patients at prices comparable to those available in other wealthy countries. Genentech will also expand its recently-launched direct-to-patient program for its essential flu medicines and make the program available via Trum...